Christina Nguyen, MD
Neuromuscular Medicine · Fountain Valley, CANPI 1508186701
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.6% of the total across 1,755 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 60 manufacturers, the largest accounting for just 14.0% — the pattern of someone who eats at a lot of different presentations.
Across 1,755 payments — averaging $18.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$5K
- UCB, Inc.$2K
- Acadia Pharmaceuticals Inc$2K
- Novartis$2K
- Neurocrine Biosciences, Inc.$2K
- Biogen$1K
- plus $20K from 54 others
What the payments were for
- Speaking & faculty fees$4281%
- Travel & lodging$2641%
- Food & beverage$31,59798%
- Education$920%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$32,381 in reported general payments places this provider in the 70th percentile of 44 neuromuscular medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 13 | $91,823 |
| NeuproRotigotine | 69 | $89,004 |
| GocovriAmantadine Hcl | 31 | $77,028 |
| HizentraImmun Glob G(Igg)/Pro/Iga 0-50 | 13 | $73,322 |
| Nurtec OdtRimegepant Sulfate | 50 | $70,929 |
| CopaxoneGlatiramer Acetate | 12 | $64,089 |
| NuplazidPimavanserin Tartrate | 11 | $54,504 |
| UbrelvyUbrogepant | 46 | $51,058 |
| InbrijaLevodopa | 13 | $50,784 |
| RytaryCarbidopa/Levodopa | 68 | $41,274 |
| RexultiBrexpiprazole | 22 | $34,796 |
| DhivyCarbidopa/Levodopa | 20 | $16,927 |
| AptiomEslicarbazepine Acetate | 12 | $14,729 |
| FycompaPerampanel | 11 | $14,065 |
| XcopriCenobamate | 11 | $13,222 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Grifols USA, LLCGamunex-C | $137 | $91,82313 claims |
| UCB, Inc.Neupro | $1,949 | $89,00469 claims |
| MDD US Operations, LLCGocovri | $1,326 | $77,02831 claims |
| CSL BehringHizentra | $609 | $73,32213 claims |
| PfizerNurtec Odt | $555 | $70,92950 claims |
| Teva Pharmaceuticals USA, Inc.Copaxone | $1,101 | $64,08912 claims |
| Acadia Pharmaceuticals IncNuplazid | $1,588 | $54,50411 claims |
| AbbVieUbrelvy | $4,524 | $51,05846 claims |
| Acorda Therapeutics, IncInbrija | $494 | $50,78413 claims |
| Amneal Pharmaceuticals LLCRytary, Mycophenolate Mofetil, Pyridostigmine Bromide | $1,104 | $44,740111 claims |
| Avion PharmaceuticalsDhivy | $352 | $16,92720 claims |
| Sunovion Pharmaceuticals Inc.Aptiom | $847 | $14,72912 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 44 neuromuscular medicine providers in California.
Other neuromuscular medicine in Fountain Valley
- Samir MacwanRancho Mirage$983K
- Ali HabibOrange$445K
- Tahseen MozaffarOrange$428K
- Jeffrey RosenfeldFresno$361K
- John DayStanford$294K
- Marwa KaiseyWest Hollywood$264K
- Namita GoyalOrange$174K
- Ana Tesi RochaPalo Alto$154K
- Jay HanOrange$126K
- Steven CramerLos Angeles$112K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.